1. In Vivo
  2. >>Archive

Start-Up Previews, April 2012

 
• By Nancy Dvorin

This Month's Profile Group, Vaccine Investment Gets A Shot In The Arm, features profiles of Genocea Biosciences, Imaxio, Selecta Biosciences and TremRx. Plus these Start-Ups Across Health Care: Bluegrass Vascular Technologies, Haldor Advanced Technologies and Targovax.

Genocea Biosciences Inc. is one of a growing number of companies betting that it can stimulate the body’s T cell response against particular antigens, and so create vaccines against pathogens never before bested by man, such as malaria, herpes, and chlamydia. Like others working to develop new vaccines, Genocea suspects that the ability to conjure cellular immunity on demand could offer not only prophylaxis, but also therapeutic options to individuals already infected by pathogens.

Imaxio SA has identified a molecule that it believes can boost the body’s recognition of many antigens, and stimulate...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Execs On The Move: October 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

A $30m Milestone And Leadership Handoff Signal New Chapter For Recursion

 
• By David Wild

Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.

How Rare Disease Advocates Are Reshaping Gene Therapy Development

 
• By David Wild

Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.